Login / Signup

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Kristian ReichKim A PappApril W ArmstrongY WasfiS LiY K ShenB RandazzoM SongAlexa B Kimball
Published in: The British journal of dermatology (2020)
The safety profile for guselkumab remains favourable through 100 weeks of treatment in patients with moderate-to-severe psoriasis.
Keyphrases
  • high intensity
  • early onset
  • double blind
  • open label
  • gestational age
  • clinical trial
  • atopic dermatitis
  • newly diagnosed
  • replacement therapy